MannKind Corporation

381 articles about MannKind Corporation

• MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference

  12/6/2021

  MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021.

• MannKind Corporation Reports 2021 Third Quarter Financial Results

  11/9/2021

  MannKind Corporation reported financial results for the quarter and nine months ended September 30, 2021.

• Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds

  11/9/2021

  MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced the closing on November 8, 2021, of its previously announced sale-leaseback transaction with an affiliate of Creative Manufacturing Properties.

• MannKind Presents Data at 21st Annual Diabetes Technology Meeting

  11/5/2021

  MannKind Corporation will present data at the 21st Annual Diabetes Technology Meeting.

• MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021

  11/2/2021

  MannKind Corporation will release its 2021 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM on Tuesday, November 9, 2021.

• Progress Update on Tyvaso DPI™ New Drug Application

  10/18/2021

  MannKind Corporation has learned that the U.S. Food and Drug Administration issued a complete response to United Therapeutics Corporation regarding the New Drug Application for Tyvaso DPI™ for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

• 

  FDA Serves Omeros, MannKind-United and Revance with CRLs

  10/18/2021

  Omeros Corporation shares were down in premarket trading after the company received a CRL for its experimental hematopoietic stem cell transplant-associated thrombotic microangiopathy treatment.
• 

  Clinical Catch-Up: October 4-8

  10/11/2021

  Another busy week for clinical trial news. Here’s a look.

• MannKind Announces First Patient Enrolled In Inhale-1 Study Of Afrezza® In Pediatric Population

  10/4/2021

  MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced the enrollment of the first pediatric patient in the INHALE-1 study.

• Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds

  9/29/2021

  MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that it has entered into a sale-leaseback transaction with an affiliate of Creative Manufacturing Properties, which will generate $102.25 million in gross proceeds upon closing.

• MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference

  9/28/2021

  MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that it will be participating at the Lytham Partners Fall 2021 Investor Conference on Tuesday, October 5, 2021 at 11:45 am.

• Mannkind Corporation Participating at Upcoming Conferences - Sep 15, 2021

  9/15/2021

  MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that it will be participating at upcoming conferences.

• MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that its Chief Executive Officer Michael Castagna, PharmD, will participate in a Fireside Chat at the H.C. Wainwright 23rd Annual Global Investment Conference which will be available on demand starting on September 13, 2021.

• MannKind Corporation Reports 2021 Second Quarter Financial Results

  8/11/2021

  MannKind Corporation reported financial results for the quarter and six months ended June 30, 2021.

• NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions

  8/4/2021

  NRx Pharmaceuticals announced it has signed an agreement with MannKind Corporation to develop a dry powder formulation of ZYESAMI™, a synthetic form of human Vasoactive Intestinal Peptide, produced by the body to help protect cells against inflammatory conditions.

• MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform

  8/4/2021

  MannKind Corporation has partnered with NRx Pharmaceuticals to evaluate the feasibility of formulating a dry powder formulation of ZYESAMI™, a synthetic form of human Vasoactive Intestinal Peptide – an endogenous substance produced by the body that helps protect cells against inflammatory conditions.

• MannKind Corporation to Hold 2021 Second Quarter Financial Results Conference Call on August 11, 2021

  8/4/2021

  MannKind Corporation will release its 2021 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM on Wednesday, August 11, 2021.

• MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021

  8/3/2021

  MannKind Corporation announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat in the BTIG Virtual Biotechnology Conference 2021 on Tuesday, August 10, 2021 at 12:30 PM (ET).

• Policy Change Allows Approval For Medicare Patients Living With Diabetes To Use Both Afrezza® And Continuous Glucose Monitoring Devices Beginning July 18

  6/28/2021

  MannKind Corporation appreciates the recent efforts of the Centers for Medicare and Medicaid Services in conjunction with the Medicare Administration Contractors to implement a policy change to the Local Coverage Determination L33822, allowing the approval to Medicare patients living with diabetes to select both Afrezza® and Continuous Glucose Monitors.

• MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29

  6/25/2021

  - Poster 923-P: Phase 2 clinical study results revealed similar tolerability and time-action profile of Technosphere® Insulin in pediatric subjects as in published data for adults; provides rationale for conducting a Phase 3 study